Locoregional Treatment of Glioblastoma With Targeted α Therapy

医学 多塔 总体生存率 内科学 胶质母细胞瘤 不利影响 肿瘤科 核医学 癌症研究 体内 生物 生物技术
作者
Leszek Królicki,Jolanta Kunikowska,Frank Bruchertseifer,Radosław Kuliński,Dariusz Pawlak,Henryk Koziara,Rafał Rola,Alfred Morgenstern,Adrian Merlo
出处
期刊:Clinical Nuclear Medicine [Lippincott Williams & Wilkins]
卷期号:48 (5): 387-392 被引量:10
标识
DOI:10.1097/rlu.0000000000004608
摘要

Glioblastoma (GB) is the most malignant primary brain tumor. Therefore, introduction of new treatment options is critically important. The aim of this study was to assess local treatment with α emitters [ 213 Bi]Bi-DOTA-substance P (SP) and [ 225 Ac]Ac-DOTA-SP.Treatment was performed as salvage therapy in patients with recurrent primary and secondary GB. [ 213 Bi]Bi-DOTA-SP with injected activity 1.85 GBq per cycle was used in 20 primary (48.2 ± 11.8 years old) and in 9 secondary (38.8 ± 10.8 years old) GB patients and [ 225 Ac]Ac-DOTA-SP in 15 primary (45.1 ± 9.9 years old) and in 6 secondary (37.8 ± 6.4 years old) GB patients with a dose escalation scheme (10, 20, and 30 MBq).Local treatment with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP was well tolerated with only few adverse effects. There was no statistically significant difference between [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP groups in survival parameters. For primary GB, survival parameters of patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows(in months): progression-free survival time, 2.7 versus 2.4; OS-d (overall survival from time of diagnosis to death from any cause), 23.6 versus 21.0; OS-t (overall survival from the start of treatment to death from any cause), 7.5 versus 5.0; and OS-r (overall survival from recurrence in primary tumors to death from any cause), 10.9 versus 12.0. Survival parameters of secondary GB patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows (in months): progression-free survival time, 5.8 versus 2.4; OS-d, 52.3 versus 65.0; OS-t, 16.4 versus 16.0; and OS-c (overall survival from conversion into secondary GB multiforme to death from any cause), 18.4 versus 36.0.The similarity results of 213 Bi or 225 Ac may suggest that the local treatment of brain tumors can be greatly simplified. The experience to date shows that local radioisotope treatment of brain tumors requires further dosimetry studies, taking into account the complexity of biological processes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
JamesPei应助nn采纳,获得10
1秒前
fanyy完成签到 ,获得积分10
1秒前
lll发布了新的文献求助10
1秒前
顾矜应助Xuan采纳,获得30
1秒前
飞翔的梦完成签到,获得积分10
2秒前
充电宝应助爱撒娇的怜珊采纳,获得150
3秒前
滴答滴发布了新的文献求助10
5秒前
烂漫的碧玉应助JerryHsc采纳,获得10
7秒前
达达发布了新的文献求助10
8秒前
悦耳忆曼完成签到,获得积分10
10秒前
12秒前
landewen完成签到 ,获得积分10
15秒前
16秒前
冷静新烟发布了新的文献求助10
16秒前
FashionBoy应助自信的碧彤采纳,获得10
17秒前
18秒前
初遇之时最暖应助panpan采纳,获得10
18秒前
凉宫八月完成签到,获得积分10
19秒前
可靠钢铁侠完成签到,获得积分10
19秒前
bear完成签到 ,获得积分10
20秒前
hoshi完成签到 ,获得积分10
21秒前
21秒前
JerryHsc完成签到,获得积分10
21秒前
21秒前
翁sir完成签到,获得积分10
21秒前
苏俊彬发布了新的文献求助10
22秒前
嘻嘻嘻完成签到,获得积分10
23秒前
laber应助初景采纳,获得50
24秒前
evens完成签到,获得积分20
25秒前
jq完成签到,获得积分10
25秒前
26秒前
DAI正杰发布了新的文献求助10
26秒前
27秒前
嘻嘻嘻发布了新的文献求助10
27秒前
谢谢大佬们完成签到,获得积分10
29秒前
Suzanne完成签到,获得积分10
31秒前
浩浩浩完成签到,获得积分10
32秒前
木易发布了新的文献求助10
32秒前
Babyblue发布了新的文献求助10
33秒前
朴素的新晴完成签到,获得积分10
34秒前
高分求助中
Principles of Economics, 11th Edition 10000
Prescott's Microbiology: 2026 Release ISE 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Environmental Leverage in Times of Climate Crisis: Product Standards, Carbon Border Measures and Preferential Trade Agreements 1000
Interactions of Vowel Quality and Prosody in East Slavic 1000
Erwählung und Berufung bei Paulus: Bedeutung, Entwicklung und Funktion einer Vorstellung in ihrem frühjüdischen und griechisch-römischen Kontext 850
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7190408
求助须知:如何正确求助?哪些是违规求助? 8827717
关于积分的说明 18637640
捐赠科研通 6824388
什么是DOI,文献DOI怎么找? 3175017
关于科研通互助平台的介绍 2326295
邀请新用户注册赠送积分活动 2149378